Routine laboratory monitoring is currently not recommended in patients receiving dabigatran
despite its considerable variation in plasma concentration. However, in certain clinical …

Background In clinical practice, physicians are given the choice of selecting one of two
dabigatran doses based on patient characteristics, with the lower dose typically used in …

Dabigatran is an oral anticoagulant that is increasingly used for atrial fibrillation (AF).
Presently, many authorities state that routine laboratory coagulation monitoring is not …

Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent
thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is …

Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …

Dabigatran, a new direct thrombin inhibitor, achieves strong anticoagulation that is more
predictable than warfarin. Nevertheless, a patient on dabigatran therapy (DT) may suffer …

Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in
patients with atrial fibrillation. In this study, we aimed to assess the associations between the …

Aims In patients with atrial fibrillation prescribed dabigatran, the aim was to examine the
correlation between plasma dabigatran concentrations and the three screening coagulation …

Background Direct oral anticoagulant dabigatran was first introduced as a fixed-dose drug
without routine coagulation monitoring, but current recommendations suggest that diluted …

Background: Dabigatran etexilate is a new oral anticoagulant for the therapy and
prophylaxis of venous thromboembolism and stroke prevention in patients with atrial …